S-2E (CAS 155730-92-0)

S-2E, also known as Sulindac sulfide, has garnered significant attention in scientific research due to its properties and mechanisms of action, particularly in the field of cancer biology. Studies have explaind its role as a nonsteroidal anti-inflammatory drug (NSAID) metabolite that exhibits anticancer effects through multiple mechanisms. One of its primary mechanisms involves the inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, leading to the suppression of prostaglandin synthesis and subsequent modulation of inflammatory pathways. Additionally, S-2E has been shown to induce apoptosis in cancer cells by activating intrinsic apoptotic pathways and disrupting mitochondrial function. Furthermore, it exerts antiproliferative effects by inhibiting cell cycle progression and angiogenesis, thereby impeding tumor growth and metastasis. Research has also highlighted its potential in combination therapy with conventional chemotherapeutic agents or targeted therapies, demonstrating synergistic effects and enhanced efficacy against various cancer types. Moreover, studies have explored its chemopreventive properties, suggesting its potential utility in preventing tumor initiation and progression. Ongoing research continues to unravel the complex molecular mechanisms underlying the anticancer activity of S-2E, paving the way for its further development as a promising agent in oncology research.